BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brukinsa (zanubrutinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brukinsa (zanubrutinib)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06669143-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06669143)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib-based M
 aintenance Therapy of Newly Diagnosed DLBCL With Initial Remission\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06669143
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594432-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06594432)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Molecular Subtype-Gu
 ided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients 
 with Central Nervous System Involvement\nEstimated primary completion: Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06594432
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549335-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06549335)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib\, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatmen
 t-naive Patients with Follicular Lymphoma (FL)\nEstimated primary completi
 on: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06549335
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561347-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06561347)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib\, Benda
 mustine\, Rituximab Prev. Untreated WM\nEstimated primary completion: 1 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06561347
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471738-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06471738)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Combination of Zanubrutinib\, Rituximab and Venetoclax in Patients With 
 Previously Untreated Follicular Lymphoma\nEstimated primary completion: 30
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanub
 rutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06471738
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06375733-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06375733)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2.\nStudy: A Study of GFH009 
 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory D
 LBCL\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06375733
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05873712-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05873712)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of 
 Richter's Syndrome\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05873712
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05939037-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05939037)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib Treatme
 nt in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyne
 uropathy\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05939037
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504199-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06504199)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Obinutuzumab\, Zanubrutinib\, and Lenalidomide Followed Short-Cycle of 
 Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06504199
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647732-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06647732)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib Plus Ri
 tuximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymp
 homa (MALT)\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06647732
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563505-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06563505)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: A Phase 2 Trial of M
 osunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Margin
 al Zone Lymphoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06563505
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04170283-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT04170283)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3.\nStudy: A Study to Evaluate 
 Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Mali
 gnancies Who Participated in BeiGene Parent Studies of Zanubrutinib\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04170283
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04515238-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT04515238)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Sequential Regimen o
 f Bendamustine Followed by Obinutuzumab (GA101)\, Zanubrutinib (BGB-3111) 
 and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL\nEstimat
 ed primary completion: February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04515238
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03824483-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT03824483)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Study of Zanubrutinib\, Obinutuzumab\, and Venetoclax in Patien
 ts With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (
 SLL)\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03824483
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923162-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Brukinsa (zanubrutinib): Phase 4 readout est. (NCT07923162)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 4.\nStudy: MACE and BTK Inhibit
 ors\nEstimated primary completion: 1 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07923162
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650723-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05650723)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymp
 hocytic Leukemia (CLL) With Response-based Obinutuzumab\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05650723
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012980-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07012980)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Glofitamab\, Polatuz
 umab Vedotin and Zanubrutinib in First-line Elderly DLBCL\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07012980
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07270835-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Brukinsa (zanubrutinib): Phase 4 readout est. (NCT07270835)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 4.\nStudy: Zanubrutinib Combine
 d With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma\nEst
 imated primary completion: April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07270835
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674810-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07674810)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Phase 2 Trial Of The Combination Of Zanubrutinib\, Sonrotocla
 x\, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocyti
 c Leukemia\nEstimated primary completion: 30 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07674810
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942507-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Brukinsa (zanubrutinib): Phase na readout est. (NCT06942507)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase na.\nStudy: Zanubrutinib Combin
 ed With BR in the First-line Treatment of Waldenström's Macroglobulinemia
 \nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06942507
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04458610-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT04458610)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Rituximab for the Treatment of Previously Untr
 eated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimate
 d primary completion: 26 May 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04458610
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04277637-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Brukinsa (zanubrutinib): Phase 1 readout est. (NCT04277637)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1.\nStudy: Study of Bcl-2 Inhib
 itor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignanci
 es\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04277637
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646666-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06646666)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: ARTA-based Chemo-fre
 e Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL 
 Ineligible for HDCT and ASCT\nEstimated primary completion: 1 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06646666
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003464-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07003464)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Phase II Trial of Zanubrutinib\, Obinutuzumab\, Bendamustine (Z
 GB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Cente
 r Study\nEstimated primary completion: 1 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07003464
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959732-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06959732)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib Combined With G-CVP in Previously Untreated FL\nEstimated p
 rimary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06959732
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05718869-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05718869)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Tafasitamab and Zanubrutinib for the Treatment of Patients With
  Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
 a\, TaZA CLL Study\nEstimated primary completion: 27 July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05718869
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261163-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07261163)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Obinutuzumab\, Zanubrutinib\, and Lenalidomide in First-line Treatment 
 of Mantle Cell Lymphoma\nEstimated primary completion: 31 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07261163
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04271956-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT04271956)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Efficacy and Safety 
 of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax fo
 r Patients With Richter Transformation\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042
 71956
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707377-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Brukinsa (zanubrutinib): Phase 2/3 readout est. (NCT05707377)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2/3.\nStudy: A Study to Examine
  the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Memb
 ranous Nephropathy\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05707377
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839247-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07839247)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib Plus Le
 nalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07839247
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973811-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06973811)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: ZR-MTX for PIOL Phas
 e II Trial\nEstimated primary completion: 30 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06973811
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271667-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07271667)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inh
 ibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and 
 Other B-cell Malignancies\nEstimated primary completion: November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07271667
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136351-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06136351)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: A Study of the Zanubrutinib Given in Combination With Bendamustine and 
 Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Pat
 ients With Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary complet
 ion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06136351
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474481-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06474481)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular L
 ymphoma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06474481
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05389293-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05389293)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Folli
 cular Lymphoma\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05389293
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06958705)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Venetoclax as Consolidation in CLL Patients Treated With BTK In
 hibitor Monotherapy\nEstimated primary completion: 1 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06735664-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Brukinsa (zanubrutinib): Phase 1 readout est. (NCT06735664)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib in Combination With Odronextamab for the Treatment
  of Patients With Richter's Transformation\nEstimated primary completion: 
 13 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zan
 ubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06735664
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427213-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06427213)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: This is a Phase II\, Open-label\, Multicentre Study of Zanubrutinib-con
 taining Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma\nEs
 timated primary completion: 30 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06427213
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405255-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07405255)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zillion: Zanubrutini
 b Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma\nEstimated p
 rimary completion: 30 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07405255
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07418190)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Efficacy and Safety of Zanubrutinib\, Rituximab\, and Lenalidomide (ZR²
 ) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymp
 homa\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07418190
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671378-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07671378)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatmen
 t-Naïve\, High-Risk CLL/SLL Patients\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07671378
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734038-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07734038)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymph
 ocytic Leukemia and Small Lymphocytic Lymphoma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07734038
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646211-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06646211)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: High-dose Methotrexa
 te Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagn
 osed PCNSL (MTZ)\nEstimated primary completion: 1 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06646211
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681195-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05681195)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib With Pe
 metrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervou
 s System (CNS) Lymphomas\nEstimated primary completion: February 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05681195
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371923-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07371923)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Application of Zanub
 rutinib-based Combination Regimens in the Treatment of Newly-diagnosed Dif
 fuse Large B-cell Lymphoma\nEstimated primary completion: 29 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07371923
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849713-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06849713)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib\, Obinutuzumab\, Sonrotoclax (BOSon) or BGB-16673\
 , Obinutuzumab\, Sonrotoclax (DOSon) in TN CLL/SLL\nEstimated primary comp
 letion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06849713
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550855-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07550855)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Sonrotoclax\, Zanubrutinib and Rituximab in Previously Untreated Patient
 s With Follicular Lymphoma\nEstimated primary completion: 30 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07550855
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299149-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07299149)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib\, Obinutuzumab Combined With Lenalidomide (ZGR) for the Tre
 atment of Untreated Follicular Lymphoma\nEstimated primary completion: 28 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07299149
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803693-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06803693)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Efficacy and Safety 
 of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL\nEstimated primary completi
 on: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/za
 nubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06803693
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558604-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06558604)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-r
 isk Mantle-cell Lymphoma\nEstimated primary completion: May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06558604
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029309-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06029309)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Mantle Cell Lymphoma.\nSt
 udy: Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma\nEstimated prima
 ry completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06029309
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918015-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06918015)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib Plus GCVP (Obinutuzumab\, Cyclophosphamide\, Vindesine\, Pr
 ednisolone) in Previously Untreated Follicular Lymphoma\nEstimated primary
  completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06918015
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259122-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07259122)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: A Phase II Clinical 
 Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibod
 y and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström
  Macroglobulinemia\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07259122
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05100862-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT05100862)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Follicular Lymphoma.\nStudy
 : A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituxima
 b in Participants With Relapsed/Refractory Follicular or Marginal Zone Lym
 phoma\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05100862
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126678-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Brukinsa (zanubrutinib): Phase na readout est. (NCT07126678)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase na\, Follicular Lymphoma.\nStud
 y: Fixed-Duration Zanubrutinib\, Bendamustine\, and Obinutuzumab (ZBG) in 
 Treatment-Naïve Advanced Stage Follicular Lymphoma\nEstimated primary com
 pletion: 15 July 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07126678
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants Wit
 h Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mantle C
 ell Lymphoma\nEstimated primary completion: 1 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522555-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280810
DTEND;VALUE=DATE:20280811
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT06522555)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3.\nStudy: The Efficacy and Saf
 ety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo D
 iffuse Large B-cell Lymphoma\nEstimated primary completion: 10 August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06522555
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812246-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07812246)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chro
 nic Lymphocytic Leukemia /Small Lymphocytic Leukemia\, ZeuS-2 Trial\nEstim
 ated primary completion: 13 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07812246
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799220-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07799220)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: A Study of Zanubrutinib\, Obinutuzumab\, and Sonrotoclax in People With
  Mantle Cell Lymphoma\nEstimated primary completion: September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07799220
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492837-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06492837)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Pat
 ients\nEstimated primary completion: 15 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06492837
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05635162-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05635162)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymp
 homa\nEstimated primary completion: October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05635162
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169331-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Brukinsa (zanubrutinib): Phase 4 readout est. (NCT07169331)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 4.\nStudy: A Study to Evaluate 
 the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-N
 aive Waldenström Macroglobulinemia\nEstimated primary completion: 31 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 169331
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463691-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06463691)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Sonrotoclax\, Zanubr
 utinib and CD20mab in Untreated MCL Patients\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanu
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06463691
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634589-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281202
DTEND;VALUE=DATE:20281203
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06634589)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2.\nStudy: A Study to Investi
 gate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination W
 ith Other Agents in Participants With Relapsed or Refractory B-Cell Malign
 ancies\nEstimated primary completion: 2 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06634589
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315373-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07315373)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Optimal Dose of Zanu
 brutinib to Treat Adult Immune Thrombocytopenia\nEstimated primary complet
 ion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07315373
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Chronic Lymphocytic Leuke
 mia.\nStudy: Mosunetuzumab for CLL MRD Clearance\nEstimated primary comple
 tion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07052695
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547866-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06547866)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Study Evaluating the
  Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Pat
 ients Previously Treated for Waldenström Macroglobulinemia\nEstimated pri
 mary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06547866
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165769-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07165769)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib\, Obinu
 tuzumab\, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splen
 ic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective\, Open-l
 abel\, Single-arm Clinical Trial\nEstimated primary completion: 31 Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0716
 5769
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514169-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07514169)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: The Efficacy and Saf
 ety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL\nEstimated 
 primary completion: 31 December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07514169
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608978-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07608978)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Efficacy and Safety 
 of Polatuzumab Vedotin in Combination With Zanubrutinib\, Rituximab\, Cycl
 ophosphamide\, Doxorubicin\, and Prednisone in Patients With Previously Un
 treated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07608978
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690761-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07690761)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Rituximab+ Zanubruti
 nib for Patients With Hairy Cell Leukemia and Hairy Cell Variant\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07690761
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06665217-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06665217)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: G-Pola-ZLP in Diffus
 e Large B-Cell Lymphoma\nEstimated primary completion: January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06665217
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899398-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07899398)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Trial to Evaluate the Efficacy and Safety of a Fitness-adapte
 d Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Tim
 e-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With T
 reatment-naïve CLL\nEstimated primary completion: 1 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07899398
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859008-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Brukinsa (zanubrutinib): Phase 1 readout est. (NCT06859008)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1\, Follicular Lymphoma.\nStudy
 : Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underr
 epresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell
  Non-Hodgkin Lymphoma\nEstimated primary completion: 31 January 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06859008
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350318-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06350318)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas\nE
 stimated primary completion: March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06350318
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548255-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Brukinsa (zanubrutinib): Phase 1 readout est. (NCT07548255)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1\, Mantle Cell Lymphoma.\nStud
 y: The Efficacy and Safety of Sonrotoclax\, Zanubrutinib Combined With Obi
 nutuzumab in MCL\nEstimated primary completion: 1 March 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07548255
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06167785-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06167785)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: A Study to Evaluate 
 Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T\nEstimate
 d primary completion: April 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06167785
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739459-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07739459)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Study of Zanubrutinib in Older Patients With Previously Untreat
 ed Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: April
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07739
 459
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735834-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT05735834)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3.\nStudy: Comparison Between R
 ituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL 
 Patients\nEstimated primary completion: May 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05735834
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594899-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07594899)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: AI-Driven Treatment 
 Strategy vs Pola-R-CHP in Untreated LBCL\nEstimated primary completion: 31
  May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7594899
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717177-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07717177)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: AI-Driven Treatment 
 Strategy vs ZR2 in Older Treatment-naive Patients With LBCL\nEstimated pri
 mary completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07717177
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846463-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06846463)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib in Pati
 ents With DLBCL and MYD88 or NOTCH1 Mutation or CD5+\nEstimated primary co
 mpletion: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06846463
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854003-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06854003)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: BRAZAN: A Randomized Phase 2 Study of Bendamustine\, Rituximab\, Cytara
 bine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/
 Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymp
 homa\nEstimated primary completion: 1 November 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06854003
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Mantle Cell Lymphoma.\nSt
 udy: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) W
 hen Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEst
 imated primary completion: 30 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664411-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06664411)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Pola-ZR2P in Previou
 sly Untreated DLBCL\nEstimated primary completion: December 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06664411
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05890352)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Ret
 urned or Did Not Respond to Treatment\nEstimated primary completion: 1 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05890352
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341191-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07341191)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mant
 le Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07341191
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890585-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06890585)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib\, Chida
 mide\, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly
  Diagnosed Double-Expressor DLBCL\nEstimated primary completion: 31 Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 90585
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682415-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07682415)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib Inducti
 on Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL
 /SLL：Stop Trial 2.0\nEstimated primary completion: 31 December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07682415
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06367374-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06367374)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/
 SLL\nEstimated primary completion: 28 February 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06367374
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563596-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06563596)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Epco\, Zanu\, Ritux for R/R FL or MZL\nEstimated primary completion: 1 M
 arch 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6563596
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505849-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20300323
DTEND;VALUE=DATE:20300324
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07505849)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lym
 phoma\nEstimated primary completion: 23 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07505849
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730542-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Brukinsa (zanubrutinib): Phase 1 readout est. (NCT06730542)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1.\nStudy: Zanubrutinib in Comb
 ination With Pola-R-CHP and High-dose Methotrexate in Patients With Second
 ary CNS Lymphoma\nEstimated primary completion: 30 April 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06730542
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503263-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06503263)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubrutinib and Len
 alidomide as Maintenance Therapy in DLBCL\nEstimated primary completion: 3
 0 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06503263
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277231-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT07277231)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutini
 b (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Pr
 eviously Untreated Chronic Lymphocytic Leukemia\nEstimated primary complet
 ion: February 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 anubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07277231
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392229-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07392229)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Zanubritnib and Anti
 -MAG Neuropathy\nEstimated primary completion: March 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07392229
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299331-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Brukinsa (zanubrutinib): Phase na readout est. (NCT07299331)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase na.\nStudy: Zanubrutinib\, Ritu
 ximab\, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymp
 homa\nEstimated primary completion: 30 April 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07299331
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824701-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Brukinsa (zanubrutinib): Phase 1 readout est. (NCT06824701)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1.\nStudy: Tazemetostat in Comb
 ination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or
  Refractory B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: Jan
 uary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6824701
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06073821-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT06073821)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Chronic Lymphocytic Leukemi
 a.\nStudy: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) C
 ompared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lym
 phocytic Leukemia (CLL)\nEstimated primary completion: February 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06073821
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544785-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06544785)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib With Obinutuzumab in Untreated Patients With Chron
 ic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary c
 ompletion: 31 May 2032. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06544785
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638722-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20340403
DTEND;VALUE=DATE:20340404
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07638722)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2.\nStudy: Testing Mosunetuzuma
 b Alone\, With Zanubrutinib\, or With Polatuzumab Vedotin for Treating Mar
 ginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment\nEs
 timated primary completion: 3 April 2034. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07638722
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474961-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Brukinsa (zanubrutinib): Phase 4 readout est. (NCT07474961)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 4.\nStudy: BLOOD-dose: A Platfo
 rm Trial Evaluating Dose Optimization in Hematological Diseases.\nEstimate
 d primary completion: December 2036. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07474961
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976763-10908@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20380831
DTEND;VALUE=DATE:20380901
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT05976763)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Mantle Cell Lymphoma.\nStud
 y: Testing Continuous Versus Intermittent Treatment With the Study Drug Za
 nubrutinib for Older Patients With Previously Untreated Mantle Cell Lympho
 ma\nEstimated primary completion: 31 August 2038. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05976763
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
